Healthcare Industry News: Cytochroma
News Release - August 13, 2007
Joel Z. Melnick, MD joins Cytochroma as Vice President, Clinical & Regulatory AffairsMARKHAM, ON, Aug. 13 (HSMN NewsFeed) - Cytochroma Inc. announced today that Joel Z. Melnick, MD has joined Cytochroma's management team as Vice President, Clinical & Regulatory Affairs. Dr. Melnick will be responsible for managing the clinical development of Cytochroma's new Vitamin D therapies and for obtaining marketing approvals from the United States Food and Drug Administration (FDA) and Canada's Therapeutic Products Directorate (TPD).
Dr. Melnick was previously Senior Medical Director in the Global Pharmaceutical Research and Development Group at Abbott Laboratories (North Chicago, IL). There, he managed clinical trials, regulatory submissions, marketing approvals and post-launch support for Zemplar® (paricalcitol) Capsules and Injection, currently one of the world's leading Vitamin D hormone replacement therapies for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD).
"We are delighted to announce the hiring of Dr. Melnick," said Charles W. Bishop, PhD, President and CEO. "He will greatly boost our ability to rapidly develop and launch products targeting CKD patients. We expect, through Dr. Melnick's leadership and proven expertise, to submit New Drug Applications to the FDA for three new Vitamin D products within the next two years."
Dr. Melnick completed his medical degree, internship, and residency in internal medicine and pediatrics at Creighton University, and completed a post-doctoral fellowship in pediatric and adult nephrology at the University of Texas Southwestern Medical Center. Dr. Melnick subsequently served as Assistant Professor of Pediatrics at Northwestern University, where he conducted research in metabolism and cardio-renal disease.
"Cytochroma has built a deep product pipeline targeting CKD, interactively working with the many leading experts on Vitamin D therapeutics and nephrology who comprise its Scientific Advisory Board. I look forward to working with such prominent and talented key opinion leaders," stated Dr. Melnick.
"With the addition of Dr. Melnick, Cytochroma has significantly increased the breadth and depth of its in-house Vitamin D product development expertise." stated Alan J. Lewis, PhD, Chairman of the Board. "Cytochroma now counts among the senior management team the key individuals responsible for developing and commercializing Hectorol® and Zemplar®, two products which dominate the US$600+ million market for Vitamin D hormone replacement therapies in North America."
About Cytochroma Inc.
Cytochroma (www.Cytochroma.com) is a specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency. The Company has an advanced portfolio of new therapies for Vitamin D insufficiency and secondary hyperparathyroidism associated with CKD. In addition, the Company is developing novel therapies to treat hyperproliferative disorders, such as cancer and psoriasis, and hyperphosphatemia.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.